Retina/Vitreous

Top Story

Eylea payments extended due to COVID-19

March 26, 2020
Blog

BLOG: Can we use fundus autofluorescence to differentiate retinoschisis from retinal detachments?

March 20, 2020
Retinoschisis is a nonprogressive degenerative splitting of the neurosensory retina, most often at the outer plexiform layer. On clinical examination, retinoschisis…

Enrollment complete in Graybug’s phase 2b wet AMD treatment trial

March 20, 2020
The final patient has been enrolled in a phase 2b trial of Graybug Vision’s wet age-related macular degeneration treatment candidate, according to a press release…
In the JournalsPerspective

Visual acuity, injection frequency decrease over time in real-world AMD study

March 19, 2020
In a retrospective study, patients with neovascular age-related macular degeneration treated with anti-VEGF injections experienced decreased visual acuity from baseline…
More Headlines »
Case Report

Mushroom-Shaped Secondary Vasoproliferative Tumor

Ophthalmic Surgery, Lasers and Imaging Retina, Volume 5
Online Only, September 1, 2012
The authors report a clinical and echographic correlation of a retinal vasoproliferative tumor that assumed a mushroom…
More »
CME

Ocular Emergencies in Giant Cell Arteritis: Preventing Permanent Vision Loss

This activity is supported by an educational grant from Genentech, Inc.

More »
Video
Meeting News

VIDEO: How to handle patients with DME and good visual acuity

January 22, 2020
More »

Eylea payments extended due to COVID-19

March 26, 2020
Regeneron will temporarily extend physician payment terms for Eylea injection purchases for 150 days in response to the COVID-19 pandemic, the…

Blog

BLOG: Can we use fundus autofluorescence to differentiate retinoschisis from retinal detachments?

March 20, 2020

Enrollment complete in Graybug’s phase 2b wet AMD treatment trial

March 20, 2020
The final patient has been enrolled in a phase 2b trial of Graybug Vision’s wet age-related macular degeneration treatment candidate, according…

In the JournalsPerspective

Visual acuity, injection frequency decrease over time in real-world AMD study

March 19, 2020
In a retrospective study, patients with neovascular age-related macular degeneration treated with anti-VEGF injections experienced decreased visual…

Meeting News

Similar success rates found for different modalities of retinal detachment repair

March 19, 2020
PHILADELPHIA — Scleral buckle, pars plana vitrectomy and combined scleral buckle and vitrectomy had similar surgical success rates for retinal…

Iveric bio postpones Zimura trial due to coronavirus

March 18, 2020
Iveric bio will delay enrollment in its second pivotal clinical trial for Zimura due to the coronavirus global pandemic, the company announced in a…

Meeting News

Follow-up important in patients with acute posterior vitreous detachment

March 17, 2020
PHILADELPHIA — Delayed retinal breaks and retinal detachments occur more often after acute posterior vitreous detachment in patients with…

Adult enrollment complete in ongoing phase 1/2 achromatopsia trial

March 16, 2020
Applied Genetic Technologies Corporation has completed enrollment in all dose groups for adult patients with achromatopsia in its phase 1/2 clinical…

Aldeyra to focus on late-stage ocular disease programs

March 12, 2020
Aldeyra Therapeutics will prioritize its ocular disease programs while placing on hold clinical development in other fields as part of a strategic…

Meeting News

Final visual outcomes worse after anti-VEGF treatment lapse

March 11, 2020
PHILADELPHIA — Patients with neovascular age-related macular degeneration receiving intravitreal anti-VEGF injections should be encouraged to…

Santen, Tracon discontinue development of wet AMD treatment

March 11, 2020
Santen and Tracon Pharmaceuticals have discontinued development of DE-122, their wet age-related macular degeneration treatment candidate, following…

Blog

BLOG: Should we stop treating patients with eplerenone for central serous chorioretinopathy?

March 10, 2020

X-linked retinitis pigmentosa gene therapy granted PRIME, ATMP designations by EMA

March 6, 2020
The European Medicines Agency has granted priority medicines and advanced therapy medicinal product designations for AAV-RPGR, an investigational…

Iridex announces second-generation MicroPulse P3 device

March 5, 2020
Iridex introduced the second generation of the MicroPulse P3 device to deliver greater stability, visualization, coupling and fit when treating…

First patient treated with CRISPR medicine in phase 1/2 trial

March 4, 2020
The first patient has been treated in a phase 1/2 trial of AGN-151587, the first in vivo CRISPR medicine to be administered in patients, according to…

Novartis provides Beovu safety update

March 4, 2020
Novartis is conducting a comprehensive product quality review of Beovu, a treatment for wet age-related macular degeneration, after the American…

Point/Counter

Which treatment paradigm — local or systemic therapy — best treats bilateral noninfectious uveitis?

Ocular Surgery News U.S. Edition, March 10, 2020
There are distinct advantages of systemic therapy in terms of achieving control in both eyes, at a steady state, and without the risks for cataract…

Cover Story

New therapies enrich noninfectious uveitis treatment landscape

Ocular Surgery News U.S. Edition, March 10, 2020
Complex, multifactorial and associated with at least 40 different disorders, uveitis is the fifth leading cause of blindness worldwide. With an…

Lindstrom's Perspective

Comanagement may be needed for best uveitis care

Ocular Surgery News U.S. Edition, March 10, 2020
Richard L. Lindstrom, MD
The accompanying cover story on uveitis is quite comprehensive, and I have only a few thoughts to add. The uveitis being discussed in this issue is…

Nightmare cases: The artificial iris

March 2, 2020
Cosmetic iris implants are non-FDA-approved procedures that can result in severe, potentially blinding complications. Patients who undergo the…

More Headlines »